Atossa Therapeutics Inc (ATOS)

04:41 AM

Charles Schwab Investment Management Inc. Lowers Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

04:41 AM

Apr 01, 2025

Atossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical Progress - MSN

Apr 01, 2025

Mar 31, 2025

Atossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on Monday - Defense World

Mar 31, 2025

Mar 29, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025

Mar 29, 2025

Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock By Investing.com - Investing.com Canada

Mar 29, 2025

Mar 29, 2025

Q1 EPS Forecast for Atossa Therapeutics Boosted by Analyst - Defense World

Mar 29, 2025

Mar 28, 2025

Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock - Investing.com India

Mar 28, 2025

Mar 28, 2025

All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy - Yahoo Finance

Mar 28, 2025

Mar 28, 2025

Atossa Therapeutics (NASDAQ:ATOS) Earns Buy Rating from HC Wainwright - Defense World

Mar 28, 2025

Mar 26, 2025

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth - Yahoo Finance

Mar 26, 2025

Mar 26, 2025

Atossa Therapeutics Inc (ATOS) Q4 2024 Earnings Call Highlights: - GuruFocus

Mar 26, 2025

Mar 26, 2025

Atossa Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Mar 26, 2025

Mar 25, 2025

Atossa Therapeutics’ Strategic Focus on Z-endoxifen for Breast Cancer Drives Buy Rating - TipRanks

Mar 25, 2025

Mar 25, 2025

Earnings call transcript: Atossa Genetics Q4 2024 beats EPS forecast - Investing.com

Mar 25, 2025

Mar 25, 2025

Atossa Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2025

Mar 25, 2025

Atossa Therapeutics Inc Reports Q4 EPS of -$0.06, Aligning with Estimates; Revenue Remains at $0 Million - GuruFocus

Mar 25, 2025

Mar 25, 2025

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

Mar 25, 2025

Mar 23, 2025

Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Tuesday - Defense World

Mar 23, 2025

Mar 21, 2025

Atossa Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView

Mar 21, 2025

Mar 20, 2025

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 20, 2025

Mar 20, 2025

Atossa Therapeutics to Host Conference Call for Q4 and Full-Year 2024 Financial Results on March 25, 2025 - Nasdaq

Mar 20, 2025

Mar 20, 2025

Atossa Therapeutics Earnings: Key Q4 and 2024 Results Coming March 25How to Listen Live - StockTitan

Mar 20, 2025

Mar 14, 2025

HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS) - Defense World

Mar 14, 2025

Mar 12, 2025

Atossa Genetics stock hits 52-week low at $0.7 amid market challenges - Investing.com Australia

Mar 12, 2025

Mar 12, 2025

Atossa Genetics stock hits 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa

Mar 12, 2025

Mar 11, 2025

Nothing is Better Than Atossa Therapeutics Inc (ATOS) stock at the moment - SETE News

Mar 11, 2025

Mar 11, 2025

Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses - TradingView

Mar 11, 2025

Mar 11, 2025

Atossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifen - TipRanks

Mar 11, 2025

Mar 11, 2025

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications - The Manila Times

Mar 11, 2025

Mar 11, 2025

Breakthrough: New Breast Cancer Drug Shows 3x Better Survival Rate Than Standard Treatment - StockTitan

Mar 11, 2025

Mar 04, 2025

Atossa Genetics stock hits 52-week low at $0.72 - Investing.com

Mar 04, 2025

Feb 24, 2025

Atossa Therapeutics faces Nasdaq delisting over bid price By Investing.com - Investing.com South Africa

Feb 24, 2025

Feb 24, 2025

Atossa Therapeutics faces Nasdaq delisting over bid price - Investing.com

Feb 24, 2025

Feb 22, 2025

Atossa Therapeutics reports progress in breast cancer treatments - MSN

Feb 22, 2025

Feb 20, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Up 5.8% in January - MarketBeat

Feb 20, 2025

Feb 19, 2025

Atossa Therapeutics Inc (ATOS) looking to reclaim success with recent performance - SETE News

Feb 19, 2025

Feb 14, 2025

Atossa Therapeutics (NASDAQ:ATOS) Stock Crosses Below 200 Day Moving AverageHere's Why - MarketBeat

Feb 14, 2025

Feb 13, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Bought by SG Americas Securities LLC - Defense World

Feb 13, 2025

Feb 10, 2025

Market Watch Highlights: Atossa Therapeutics Inc (ATOS) Ends on an Downturn Note at 0.77 - The Dwinnex

Feb 10, 2025

Feb 10, 2025

Investing in Atossa Therapeutics Inc (ATOS) Is Getting More Attractive - Knox Daily

Feb 10, 2025

Feb 08, 2025

Atossa Therapeutics faces patent setback, continues development - MSN

Feb 08, 2025

Feb 07, 2025

FY2029 Earnings Forecast for ATOS Issued By HC Wainwright - MarketBeat

Feb 07, 2025

Feb 06, 2025

What is HC Wainwright's Estimate for ATOS FY2029 Earnings? - MarketBeat

Feb 06, 2025

Feb 05, 2025

Atossa Therapeutics Congratulates Board Director Dr. Tessa - GlobeNewswire

Feb 05, 2025

Feb 05, 2025

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care - The Manila Times

Feb 05, 2025

Feb 05, 2025

Major CDC Grant Fuels Revolutionary Breast Cancer Care Program in NYC - StockTitan

Feb 05, 2025